1849 bio GTM brain

1849 bio develops ore-specific engineered microbes to help mining operators recover copper from low-grade stockpiles.

category

Biomining and copper bioleaching

market profile

  • text: Low-grade copper stockpiles can contain substantial metal but may be uneconomic to process with conventional methods.
  • text: Biomining developers are pursuing microbial and other extraction approaches for difficult copper ores and existing heaps.

personas

  • title: Mine general manager
    pains:
    • Low-grade stockpiles tie up copper value without meeting economic recovery thresholds
    • New processing technologies must fit production schedules and site constraints
  • title: Metallurgy and heap leach superintendent
    pains:
    • Chalcopyrite and variable ore composition can limit copper recovery
    • A lab result must translate to repeatable performance in existing leaching infrastructure
  • title: Mining innovation or technical services director
    pains:
    • Evaluating emerging extraction technologies requires ore-specific evidence and pilot design
    • Must balance recovery upside with deployment, permitting and operational risk

icp

  • text: Copper mine operators with low-grade ore stockpiles or challenging chalcopyrite deposits and existing leaching infrastructure.
  • text: Mining companies with metallurgical teams able to provide ore samples and sponsor a site-specific pilot; no firm size is stated.

message pillars

  • text: Recover more copper from material that is difficult to process economically.
  • text: Tailor the microbial solution to the ore.
  • text: Integrate into existing site processes.
  • text: Begin with sample analysis and a pilot discussion.

objections

  • objection: Will engineered microbes work on our particular ore?
    response: Start with ore analysis and independently measured test results, then establish a site-specific pilot and control.
  • objection: Will deployment interrupt production or require a new plant?
    response: The company says its approach uses existing leaching infrastructure; validate integration and operating conditions at the site.
  • objection: Can laboratory recovery translate into economic mine-scale performance?
    response: Agree recovery, kinetics, cost, environmental and scale-up measures before the pilot; the site's recovery figures are company claims.

competitors

  • name: Endolith
    why: Develops microbial systems for copper recovery from heap leaching.
  • name: Jetti Resources
    why: Offers technology for extracting copper from challenging ores.
  • name: Ceibo
    why: Develops technology for improved copper extraction.

keywords

  • copper bioleaching technology
  • chalcopyrite copper recovery
  • low grade copper ore processing
  • heap leach copper recovery
  • biomining microbes
  • copper stockpile recovery
  • engineered microbes mining

voice

  • Scientifically grounded
  • Commercially focused
  • Practical about integration

signals

  • text: A copper producer has large low-grade stockpiles or chalcopyrite resources below current economic recovery thresholds.
  • text: An operator with heap leach capacity is seeking a pilot to increase recovery without building a new processing plant.

stack

  • Microbial engineering
  • High-throughput screening
  • Ore microbiome and mineral analysis

pricing

model: unknown

motion

sales_led

channels

  • Direct sales
  • Mining industry advisors
  • LinkedIn
  • Pilot partnerships

confidence

medium

Founders

  • name: Jai Padmakumar
    title: Founder/CEO
    role: CEO
    bio: Co-founder and CEO of 1849 bio. I get excited working on difficult problems with outsized impacts if you can solve them. I studied Microbiology and Applied Math at the University of Washington before doing my PhD at MIT in a synthetic biology lab. I've spent my time pushing the limits of what’s possible in bioengineering. 1849 is my second startup, the first of which I co-founded during grad school and led the early science at.
  • name: Yongjin Park
    title: Founder
    role: Founder
    bio: I am the co-founder and CSO of 1849 bio. I studied chemical engineering at KAIST and did my PhD at MIT in the Department of Biological Engineering. During my PhD, I developed core technology used in the world's first engineered probiotic that went into clinical trial. After completing PhD, I worked in deep biotech companies, developing microbial products that were administered to over 6M acres of farmland in the US (about the area of Belgium!).

Back to YC companies